皮肤与性病指南

订阅

MedSci主页 / 所有栏目 / 皮肤与性病指南

本维莫德乳膏治疗银屑病专家指导意见

2021-06-30 中华医学会皮肤性病学分会 中国皮肤性病学杂志.2021.35(6):707-711.

银屑病本维莫德乳膏

本维莫德乳膏是我国拥有完整自主知识产权的国家1 类新药，对银屑病发病过程中的多个环节，包括抗炎、调节表皮角质形成细胞角化、减少真皮血管新生等具有调节作用，在轻中度寻常性银屑病治疗中具有良好疗效和安全性

中文标题：

本维莫德乳膏治疗银屑病专家指导意见

发布机构：

中华医学会皮肤性病学分会

发布日期：

2021-06-30

简要介绍：

本维莫德乳膏是我国拥有完整自主知识产权的国家1 类新药，对银屑病发病过程中的多个环节，包括抗炎、调节表皮角质形成细胞角化、减少真皮血管新生等具有调节作用，在轻中度寻常性银屑病治疗中具有良好疗效和安全性。为了科学有效地使用本维莫德乳膏治疗轻、中度斑块型银屑病，中华医学会皮肤性病学组召集相关专家制定本指导意见，以本维莫德的药理作用机制、治疗银屑病的临床试验结果以及针对毒副作用的动物实验结果为依据，目的为规范、合理、安全地使用本维莫德乳膏治疗银屑病。

相关资料下载：
[AttachmentFileName(sort=1, fileName=本维莫德乳膏治疗银屑病专家指导意见_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b4e271c00212804d, title=本维莫德乳膏治疗银屑病专家指导意见, enTitle=, guiderFrom=中国皮肤性病学杂志.2021.35(6):707-711., authorId=0, author=, summary=本维莫德乳膏是我国拥有完整自主知识产权的国家1 类新药，对银屑病发病过程中的多个环节，包括抗炎、调节表皮角质形成细胞角化、减少真皮血管新生等具有调节作用，在轻中度寻常性银屑病治疗中具有良好疗效和安全性, cover=https://img.medsci.cn/2021715/1626282664858_2020535.jpg, journalId=0, articlesId=null, associationId=182, associationName=中华医学会皮肤性病学分会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Jun 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>本维莫德乳膏是我国拥有完整自主知识产权的国家1 类新药，对银屑病发病过程中的多个环节，包括抗炎、调节表皮角质形成细胞角化、减少真皮血管新生等具有调节作用，在轻中度寻常性银屑病治疗中具有良好疗效和安全性。为了科学有效地使用本维莫德乳膏治疗轻、中度斑块型银屑病，中华医学会皮肤性病学组召集相关专家制定本指导意见，以本维莫德的药理作用机制、治疗银屑病的临床试验结果以及针对毒副作用的动物实验结果为依据，目的为规范、合理、安全地使用本维莫德乳膏治疗银屑病。</p> </div> </div> </div>, tagList=[TagDto(tagId=4418, tagName=银屑病), TagDto(tagId=113469, tagName=本维莫德乳膏)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤与性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=4418, guiderKeyword=银屑病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6845, appHits=119, showAppHits=0, pcHits=634, showPcHits=6726, likes=0, shares=13, comments=6, approvalStatus=1, publishedTime=Thu Jul 15 01:51:49 CST 2021, publishedTimeString=2021-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 15 01:11:10 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 13:32:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=本维莫德乳膏治疗银屑病专家指导意见_.pdf)])
本维莫德乳膏治疗银屑病专家指导意见_.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198200, encodeId=592a1198200fc, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb56491939, createdName=ms9000001592007115, createdTime=Mon Feb 28 23:32:35 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066985, encodeId=938d106698519, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:50:28 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057878, encodeId=ca1f105e878ab, content=了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a1a5114704, createdName=14621e41m98暂无昵称, createdTime=Tue Oct 05 12:37:00 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051854, encodeId=bf8810518544d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:12 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2022-02-28 ms9000001592007115

    受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198200, encodeId=592a1198200fc, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb56491939, createdName=ms9000001592007115, createdTime=Mon Feb 28 23:32:35 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066985, encodeId=938d106698519, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:50:28 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057878, encodeId=ca1f105e878ab, content=了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a1a5114704, createdName=14621e41m98暂无昵称, createdTime=Tue Oct 05 12:37:00 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051854, encodeId=bf8810518544d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:12 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-11-04 ms9000000291054786

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198200, encodeId=592a1198200fc, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb56491939, createdName=ms9000001592007115, createdTime=Mon Feb 28 23:32:35 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066985, encodeId=938d106698519, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:50:28 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057878, encodeId=ca1f105e878ab, content=了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a1a5114704, createdName=14621e41m98暂无昵称, createdTime=Tue Oct 05 12:37:00 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051854, encodeId=bf8810518544d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:12 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-10-05 14621e41m98暂无昵称

    了解了解

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198200, encodeId=592a1198200fc, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abb56491939, createdName=ms9000001592007115, createdTime=Mon Feb 28 23:32:35 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1066985, encodeId=938d106698519, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd875691647, createdName=ms9000000291054786, createdTime=Thu Nov 04 16:50:28 CST 2021, time=2021-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057878, encodeId=ca1f105e878ab, content=了解了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a1a5114704, createdName=14621e41m98暂无昵称, createdTime=Tue Oct 05 12:37:00 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051854, encodeId=bf8810518544d, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:31:12 CST 2021, time=2021-09-16, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

相关指南

2021 共识声明：孕前、孕中、产后以及哺乳期银屑病的管理

国外皮肤性病相关专家小组（统称） · 2021-03-21

EuroGuiDerm寻常型银屑病全身治疗指南-第1部分：治疗和监测建议

欧洲皮肤病学论坛(EDF,European Dermatology Forum) · 2021-02-03

EuroGuiDerm寻常型银屑病的全身治疗指南-第2部分：特定的临床和合并症

欧洲皮肤病学论坛(EDF,European Dermatology Forum) · 2021-02-03

2021 共识建议：中重度斑块型银屑病患者的达标治疗

国外皮肤性病相关专家小组（统称） · 2021-01-11

2020 欧洲指南：寻常型银屑病的系统治疗—第1部分：治疗和监测建议

欧洲皮肤病与性病学会(EADV,European Academy of Dermatology and Venereology) · 2020-11-30

2020 BAD指南：银屑病生物治疗

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2020-03-18

拓展阅读

银屑病及银屑病性关节炎的指南：第5部分.银屑病的光疗及光化学疗法的治疗指南（AAD 2010）

美国皮肤病学会(AAD,American Academy of Dermatology) · 2010-01-01

2010 银屑病关节炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-09-01

银屑病及银屑病性关节炎的指南：第6部分.关于银屑病及银屑病性关节炎的治疗指南：基于病例及研究的结论（AAD 2011）

美国皮肤病学会(AAD,American Academy of Dermatology) · 2011-02-07

2011 EULAR共识：银屑病关节炎的药物治疗

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2011-09-27

2012 寻常性银屑病的常用外用药物治疗共识

中华医学会皮肤性病学分会 · 2012-04-30

2012 BSR/BHPR指南：应用生物制剂治疗银屑病关节炎

英国风湿病学会(BSR,British Society for Rheumatology) · 2013-07-25